Sanofi (SNY)
| Market Cap | 105.42B -13.6% |
| Revenue (ttm) | 54.60B +4.8% |
| Net Income | 8.71B +19.9% |
| EPS | 3.58 +23.0% |
| Shares Out | 1.20B |
| PE Ratio | 12.10 |
| Forward PE | 8.90 |
| Dividend | $1.76 (4.03%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 2,827,823 |
| Open | 44.70 |
| Previous Close | 43.75 |
| Day's Range | 43.79 - 44.72 |
| 52-Week Range | 40.89 - 52.68 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 55.06 (+25.74%) |
| Earnings Date | Jul 30, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $55.06, which is an increase of 25.74% from the latest price.
News
Sanofi announces Executive Committee to support next strategic chapter
Sanofi (SNY) announced an evolution of its Executive Committee. Effective September 1, Sanofi’s Executive Committee will comprise: Francois Roger, EVP, Finance; Paulo Fontoura, EVP, Head of Research &...
Sanofi: Sanofi evolves its Executive Committee to support its next strategic chapter
Sanofi evolves its Executive Committee to support its next strategic chapter Paris, July 21, 2026. Sanofi today announced an evolution of its Executive Committee, bringing together a focused leader...
Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter
Sanofi evolves its Executive Committee to support its next strategic chapter Paris, July 21, 2026. Sanofi today announced an evolution of its Executive Committee, bringing together a focused leadershi...
Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase
Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase
Aqemia and Sanofi Expand Their Research Collaboration
PARIS & LONDON--(BUSINESS WIRE)-- #DrugDiscovery--Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion ...
Sanofi sues Pfizer, Moderna over COVID shot technology
Sanofi has sued Pfizer and Moderna , alleging that their COVID-19 vaccines infringe several of the French pharmaceutical company's patents.
Sanofi (SNY) Secures FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma
Sanofi (SNY) Secures FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma
Sanofi (SNY) Receives FDA Approval for Subcutaneous Sarclisa Escena
Sanofi (SNY) Receives FDA Approval for Subcutaneous Sarclisa Escena
Sanofi Says FDA Approves Sarclisa Escena SC As First Anticancer Treatment Via On-body Injector
(RTTNews) - French drug major Sanofi SA (SNYNF, SNY) announced Friday that the US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa Escena administered via the CirCLIQ on-body...
Sanofi: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena administered via the CirCLIQ on-body injector (OBI) offers a...
Sanofi announces subcutaneous Sarclisa Escena approved in U.S.
The U.S. Food and Drug Administration has approved subcutaneous Sarclisa Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma across all existing in...
Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
US FDA approves Sanofi's wearable injector form of blood cancer drug
The U.S. Food and Drug Administration said on Friday it has approved Sanofi's blood cancer drug, Sarclisa, which can be given under the skin through a wearable injector, offering multiple m...
Sanofi price target lowered to $49 from $52 at Morgan Stanley
Morgan Stanley analyst Sarita Kapila lowered the firm’s price target on Sanofi (SNY) to $49 from $52 and keeps an Equal Weight rating on the shares. Sanofi appears set for…
EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour
The European Commission said on Wednesday it would seek feedback on commitments offered by French pharmaceutical company Sanofi to address concerns that it may have breached competition rules in ...
Sanofi SA (SNY) Shares Surge 3.7% -- What GF Score of 68 Tells Investors
Sanofi SA (SNY) Shares Surge 3.7% -- What GF Score of 68 Tells Investors
Sanofi: Availability of the aide-mémoire for Q2 2026 results
Availability of the aide-mémoire for Q2 2026 results Paris, France - July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi....
Press Release: Availability of the aide-mémoire for Q2 2026 results
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com...
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows
When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typical yields. The stocks listed here haven't been doing well this year, but they offer some attractive d...
Sanofi's Nexviazyme Achieves Key Endpoints In Infantile-Onset Pompe Disease Phase 3 Study
(RTTNews) - Sanofi (SNY) announced that Nexviazyme (avalglucosidase alfa) met all primary secondary endpoints in the Baby-COMET Phase 3 trial for infantile-onset Pompe disease. The study showed that t...
Sanofi (SNY) Reports Positive Phase 3 Results for Nexviazyme in Pompe Disease
Sanofi (SNY) Reports Positive Phase 3 Results for Nexviazyme in Pompe Disease
Sanofi's Nexviazyme Meets Main Goal In Phase 3 Baby-COMET Study
PARIS (dpa-AFX) - Sanofi SA (SNY) said on Tuesday that its Phase 3 Baby-COMET study of Nexviazyme met its primary endpoint in treatment-naïve pediatric patients aged six months and younger with in...
Sanofi: Sanofi's Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi's Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, ...
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
Sanofi Faces EU Probe With Fines Possibly Reaching 10%
Sanofi Faces EU Probe With Fines Possibly Reaching 10%